Amgen (AMGN) delivered a complex but ultimately reassuring message to investors today (2026-08-04), reporting second-quarter 2026 results that significantly surpassed Street estimates on both revenue and non-GAAP earnings per share. In the same breath, the biotechnology giant raised its full-year 2026 financial guidance, painting a picture of robust performance from its diversified portfolio. However, this good news arrived with an asterisk: the announcement that Amgen would halt further development of AMG 513, an early-stage obesity candidate, allowing its Phase 1 trial only to complete follow-up for enrolled participants.
Despite the discontinuation of AMG 513, the market's immediate reaction was positive. Amgen shares closed at $390.02, up $11.15, or 2.94%, versus yesterday's close, trading near its 52-week high of $398.00. This suggests that investors viewed the strength of Amgen’s core business and the positive outlook as significantly outweighing the setback of an early-stage pipeline asset. Robert A. Bradway, Amgen’s Chairman and CEO, underscored this confidence, stating that the company’s "six key growth drivers grew 26% year over year, generating nearly 70% of second-quarter product sales" and expressing conviction in delivering "growth well into the next decade." The challenge now is to determine if this initial market optimism is justified, given the ongoing evolution of Amgen's pipeline and its valuation.
Amgen’s second-quarter 2026 financial results demonstrate a clear acceleration in its core business. Total revenues climbed to $10.054 billion, marking a 9.5% increase year-over-year from Q2 2025. This strong top-line performance fueled non-GAAP diluted earnings per share (EPS) of $6.29, up 4.5% from $6.02 in the prior year's period. These figures comfortably surpassed consensus analyst expectations of approximately $9.43 billion in revenue and $5.62 in EPS, translating to a revenue beat of 6.6% and an EPS beat of 12%.
The company also notably uplifted its full-year 2026 guidance. The revised revenue outlook now stands at $38.2 billion to $39.4 billion, with the midpoint of $38.8 billion representing a $1.0 billion, or 2.6%, increase from the previous midpoint of $37.8 billion given in Q1 2026. Similarly, non-GAAP EPS guidance was raised to $22.30 to $23.50, with the new midpoint of $22.90 signaling a $0.50, or 2.2%, bump from the prior $22.40. This substantial guidance raise indicates robust underlying momentum, especially when considering the simultaneous discontinuation of an early-stage pipeline asset.
| Period | Total Revenues ($bn) | YoY Revenue Growth | Non-GAAP EPS ($) | YoY Non-GAAP EPS Growth | Notes |
|---|---|---|---|---|---|
| Q2 2026 | 10.054 | +9.5% | 6.29 | +4.5% | Beat consensus, raised FY26 guidance. |
| Q1 2026 | 8.618 | +6.0% | 5.15 | +5.1% | First 2026 guidance lift. |
| Q4 2025 | 9.866 | +9.0% | 5.29 | n/a | Strong finish to 2025. |
| Q3 2025 | 9.557 | +12.0% | 5.64 | +1.1% | MariTide optimism highlighted. |
| Q2 2025 | 9.179 | +9.0% | 6.02 | +21.1% | Baseline for Q2 2026 comparisons. |
The company's strong free cash flow generation further solidifies its financial position, reaching $3.5 billion in Q2 2026, a substantial increase from $1.9 billion in Q2 2025. With approximately $14.0 billion in cash and equivalents on hand against $57.3 billion in debt, Amgen maintains significant liquidity, enabling it to fund its dividend commitments, planned share repurchases of up to $3.0 billion for 2026, and continued investment in its late-stage pipeline, including the flagship obesity program MariTide.
The significant revenue beat and raised guidance are overwhelmingly driven by volume growth in Amgen’s key product franchises, rather than price increases. This distinction is crucial for understanding the sustainability of Amgen's growth trajectory. Murdo Gordon, Amgen’s EVP of Global Markets and Policy, articulated this strategy, noting, "We are growing because we are serving more patients at lower unit prices. We would anticipate in the long range for that trend to continue." This indicates a deliberate focus on market penetration and patient access, a more resilient growth mechanism in the often-scrutinized pharmaceutical industry.
Amgen’s "six key growth drivers" are performing exceptionally well, collectively expanding by 26% year-over-year and accounting for nearly 70% of the second-quarter’s $9.537 billion in product sales. Leading this charge are Repatha (evolocumab) and Evenity (romosozumab). Repatha, a PCSK9 inhibitor for hyperlipidemia, saw its sales surge by 37% year-over-year to $953 million in Q2 2026. Growth was propelled by increased urgency to treat patients, particularly in high-risk primary prevention, where it has shown a 31% reduction in major adverse cardiovascular events (MACE).
Evenity, a bone-builder for osteoporosis, posted an equally impressive 38% year-over-year sales increase, reaching $714 million. This growth is predominantly volume-driven, with Evenity maintaining a commanding 65% market share in the U.S. bone-builder market as of Q1 2026. Beyond these two, other strong contributors included TEZSPIRE (severe asthma) with 42% YoY growth to $486 million, UPLIZNA (NMOSD, IgG4-RD, gMG) with 90% YoY growth to $335 million, and PAVBLU (biosimilar aflibercept) with 90% YoY growth to $287 million. These figures collectively highlight a diversified portfolio with robust individual product performance, underpinning Amgen’s ability to grow despite ongoing price pressure and biosimilar erosion in older franchises like Prolia and Otezla.
The decision to discontinue future development of AMG 513, an early-stage (Phase 1) obesity asset, might seem like a significant blow given the immense excitement surrounding the obesity drug market. However, a deeper look into Amgen's strategy suggests this is more a disciplined portfolio optimization than a systemic failure. AMG 513 had previously faced an FDA clinical hold, later lifted, but its mechanism of action was never publicly disclosed, limiting transparency. The company's Q2 2026 press release simply stated, "Future development of AMG 513 will be discontinued. A Phase 1 study of AMG 513 in adults living with obesity will remain ongoing to follow enrolled participants through completion of the study." No explicit safety or efficacy rationale was provided for the halt.
Crucially, Amgen's flagship obesity program, MariTide (maridebart cafraglutide), remains fully intact and is, in fact, being aggressively expanded. MariTide, a first-of-its-kind antibody-peptide conjugate that targets GIPR antagonism and GLP-1 receptor agonism, is already in a broad Phase 3 program. This MARITIME program encompasses multiple trials for chronic weight management, cardiovascular and heart failure outcomes, obstructive sleep apnea, type 2 diabetes, and even a "SWITCH" study designed to transition patients from weekly GLP-1s (like semaglutide or tirzepatide) to MariTide’s monthly or less frequent dosing.
Amgen has a history of strategically pruning its pipeline to focus resources on higher-conviction assets. For instance, in 2024, it discontinued AMG 786, an oral obesity candidate, to concentrate on MariTide. Similarly, in Q1 2026, it halted development of AMG 193, an oncology asset. The discontinuation of AMG 513 aligns with this pattern of disciplined R&D, suggesting that while the drug represented optionality, its removal does not materially impair Amgen’s primary obesity strategy, which is anchored firmly on MariTide's extensive late-stage development. Given that AMG 513 had no reported commercial revenues and was in its earliest development phase, its financial impact on Amgen’s near- to medium-term outlook is negligible.
Despite Amgen’s robust Q2 performance and strategic pipeline management, several concrete risks linger, contributing to a bear case that investors should acknowledge. These include substantial debt, legacy product erosion, and the concentrated nature of Amgen’s obesity bet.
First, Amgen carries a considerable debt load. As of Q2 2026, the company reported $57.3 billion in outstanding debt against $14.0 billion in cash, implying net debt of approximately $43.3 billion. Furthermore, a significant portion of this debt, totaling $11.386 billion, is due over the next three years (2026-2028). While Amgen's strong free cash flow of $3.5 billion in Q2 helps service these obligations, these maturities, combined with annual dividend payouts (around $5.44 billion) and up to $3.0 billion in share repurchases, could limit flexibility for large-scale M&A or accelerated R&D if pipeline or market conditions sour.
Second, the company continues to face revenue erosion from legacy products. In Q2 2026, Prolia sales declined 32% year-over-year to $759 million due to biosimilar launches, Otezla fell 21% to $491 million, and Enbrel was down 4% to $580 million. These declines, totaling over $600 million in lost revenue in just one quarter compared to the prior year, create a significant drag that Amgen’s growth drivers must continuously overcome. Moreover, Evenity’s US antibody patents expired in April 2026, and while secondary patents extend to 2031-2033, the entry of biosimilars could begin to erode Evenity's impressive $2.8 billion annualized run rate within the next few years. This risk is amplified by the experience of Prolia/XGEVA, where Amgen explicitly expects accelerated sales erosion in 2026 following biosimilar launches.
Finally, the discontinuation of AMG 513, while strategically sound, underscores a concentration risk in Amgen’s obesity pipeline. With AMG 786 also halted in 2024, Amgen’s primary obesity upside now rests almost entirely on MariTide. While MariTide is a promising asset with a broad Phase 3 program, its Phase 2 data showed strong efficacy but also high discontinuation rates (10-29%) and significant gastrointestinal side effects (43-92% vomiting rates). If MariTide fails to demonstrate improved tolerability or falls short on key Phase 3 endpoints, Amgen would lack a clear second-line obesity candidate to pivot to, leaving it highly dependent on its existing, non-obesity growth drivers for future revenue acceleration. This singular bet contrasts with competitors like Eli Lilly and Novo Nordisk, who often have multiple obesity assets in various stages of development.
Wall Street analysts currently hold a largely neutral view on Amgen, with the consensus rating leaning towards "Hold." Across 30 analysts, the sentiment is mixed, with 11 Buy ratings, 15 Hold ratings, and 2 Sell ratings. This dispersion reflects lingering uncertainties around Amgen’s long-term growth profile, balancing the strength of its core franchises against the risks of patent cliffs and the competitive, high-stakes obesity market.
| Firm | Rating | Price Target ($) | Date |
|---|---|---|---|
| UBS Group | Buy | 420 | 2026-07-13 |
| Barclays | Equal Weight | 360 | 2026-07-29 |
| Morgan Stanley | Equal Weight | 333 | 2026-07-08 |
| Truist Financial | Hold | 340 | 2026-07-07 |
| Cantor Fitzgerald | Neutral | 350 | 2026-07-06 |
| BMO Capital Markets | Outperform | 400 | 2026-07-01 |
| Mizuho | Neutral | 303 | 2026-06-16 |
| Piper Sandler | Overweight | 427 | 2026-05-14 |
| Rothschild & Co | Sell | 200 | 2026-02-18 |
The average 12-month price target for Amgen sits around $357-$360, with a notable range stretching from a low of $200 to a high of $427. At today’s closing price of $390.02, Amgen trades approximately 9% above this consensus average. This premium suggests that the market has already factored in much of the good news from Q2 2026, including the guidance raise and the robust performance of its growth drivers, alongside some of the anticipated upside from MariTide. However, the fact that the stock is still trading about 9.5% below the highest analyst target of $427 indicates there is some, albeit limited, room for further upside if the company continues to execute flawlessly and exceeds expectations. Conversely, the significant gap to the low target of $200 highlights the potential for substantial downside if the bear case materializes, demonstrating the Street's considerable disagreement on Amgen's long-term value.
The most potent argument against an "overblown reaction" to the AMG 513 halt is not about AMG 513 itself, but rather Amgen's increasing reliance on MariTide as its sole advanced obesity asset, and the looming patent cliff for Evenity. Critics might contend that while AMG 513 was an early-stage backup, its discontinuation, coupled with the prior halt of oral candidate AMG 786, paints a picture of a pipeline struggling for depth in a multi-billion dollar market where competitors often boast multiple shots on goal. This concentration means Amgen's entire obesity optionality, which contributes significantly to its premium valuation, now hinges on MariTide's Phase 3 execution. If MariTide were to falter, Amgen has no clear second-line obesity candidate ready to pivot to, leaving a significant gap in its long-term growth narrative.
However, this objection, while strong, overlooks a critical aspect of Amgen’s current performance: its robust core business. The raised 2026 guidance, which now sits $1.0 billion higher than prior estimates at its midpoint, is explicitly driven by the exceptional performance of assets like Repatha and Evenity, not by any speculative future revenue from MariTide. These six key growth drivers collectively expanded 26% year-over-year in Q2 2026, accounting for nearly 70% of product sales. This means Amgen's near-term financials, including its ability to service debt and fund R&D, are anchored in proven commercial success, not pipeline optionality. The stock's current implied forward P/E of approximately 17.0x, based on the company’s own raised FY26 non-GAAP EPS midpoint of $22.90, suggests the market isn't wildly overpricing future obesity success to begin with.
While the Evenity patent cliff (antibody patents expired in April 2026) is a valid long-term concern, its current annualized run rate of nearly $2.9 billion, supported by 38% year-over-year growth, provides a substantial buffer. Amgen’s history of managing patent expirations, though not without challenges as seen with Prolia, suggests it can mitigate some of the impact through secondary patents and expanded indications for its remaining growth portfolio. Therefore, the "overblown" thesis for the AMG 513 halt holds: the market’s initial positive reaction today was justified by the tangible, immediate strength of Amgen’s core business and its updated outlook. The long-term verdict, however, will heavily depend on MariTide's upcoming Phase 3 clinical readouts. A material slowdown in the aggregated growth rate of Amgen's six key growth drivers to below 15% year-over-year in the next two consecutive quarters would decide if this nuanced optimism is misplaced.
Amgen (AMGN) presents a compelling dichotomy: a highly disciplined pharmaceutical company with a robust and accelerating core business, simultaneously making a concentrated bet on the lucrative obesity market. Its second-quarter 2026 results and raised full-year guidance underscore the strength of its diversified portfolio, particularly the rapid growth of Repatha and Evenity. The decision to discontinue AMG 513, an early-stage obesity candidate, while initially perceived as a setback, appears to be a calculated move to streamline resources towards its flagship MariTide program, a rational approach in the high-stakes world of drug development. The market's positive reaction to this news, seeing shares rally to near 52-week highs, confirms that investors are prioritizing tangible financial performance and strategic focus over early-stage optionality.
However, the stock is not without its challenges. Trading above Wall Street's consensus price targets, Amgen carries a premium valuation that places significant reliance on the successful execution and commercialization of MariTide. The company's substantial debt load and the looming patent expirations for key drugs like Evenity also represent tangible risks that could constrain future growth and capital allocation if MariTide fails to meet expectations. The next several quarters will be crucial in demonstrating MariTide's tolerability and efficacy in its broad Phase 3 program.
Given Amgen’s strong cash flow and current trajectory, we take a Neutral stance. While the core business is performing exceptionally, the market has already priced in a good portion of this success and MariTide's anticipated contribution.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
